In the training set, ER status (FDR-adjusted p-value = 0.02) and molecular subtype (FDR-adjusted p-value = 0.005) were statistically significant between HER2-low and HER2-zero breast cancer patients. This evidence concerns the gene ESR1 and breast cancer.